Scarica l'app Stockscreener
36.27
9.21%
3.06
Dopo l'orario di chiusura:
37.63
1.36
+3.75%
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Is Avidity Biosciences Inc. a good long term investmentFree Stock Market Trend Analysis - PrintWeekIndia
How Avidity Biosciences Inc. stock reacts to Fed policy changesFree Smart Trading Workshop - jammulinksnews.com
Avidity Biosciences shares climb after FDA grants Breakthrough Therapy designation - MSN
Avidity Biosciences shares rise 1.80% premarket after receiving FDA Breakthrough Therapy designation for DMD treatment. - AInvest
What drives Avidity Biosciences Inc. stock priceOverwhelming profit margins - jammulinksnews.com
Avidity Biosciences Gains FDA Breakthrough Therapy Designation - TipRanks
Why Avidity Biosciences Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - beatles.ru
Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha
FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada
Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - PR Newswire
What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com
Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive (NASDAQ:RNA) - Seeking Alpha
RNA News Today | Why did Avidity Biosciences stock drop today? - MarketBeat
Goldman Sachs resumes coverage on Avidity Biosciences stock with Buy rating - Investing.com Canada
Avidity Biosciences, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Avidity Biosciences, Inc Rings the Opening Bell - Nasdaq
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces key milestones - Investing.com
Avidity Biosciences, Inc.(NasdaqGM: RNA) added to Russell 3000E Value Index - MarketScreener
(RNA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications - TipRanks
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com India
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):